Xilio Therapeutics, Inc. (XLO) - Form 8-K Summary
Business Context and Reporting Period
Xilio Therapeutics, Inc., a Delaware corporation, filed this Current Report on Form 8-K on February 11, 2026. The filing discloses the entry into a material definitive agreement regarding a capital raise. The Company is an emerging growth company listed on the Nasdaq Capital Market.
Key Financial Metrics and Transaction Details
- Transaction Type: Underwritten offering of pre-funded warrants.
- Security Issued: Pre-funded warrants to purchase up to 74,780,300 shares of common stock.
- Offering Price: $0.5349 per Pre-Funded Warrant.
- Exercise Price: $0.0001 per share of common stock.
- Estimated Net Proceeds: Approximately $37.1 million (after underwriting discounts, commissions, and estimated offering expenses).
- Underwriter: Leerink Partners LLC.
- Expected Closing Date: On or about February 13, 2026.
The filing does not provide specific revenue, profit, cash flow, margin, or debt figures for the reporting period, as this is a transactional filing rather than a periodic financial report.
Material Changes and Terms
The primary material change is the execution of the Underwriting Agreement. Key terms include:
- Exercise Limitations: Holders are prohibited from exercising warrants if it would result in beneficial ownership exceeding 4.99% (or up to 19.99% at the holder's election) of the Company's outstanding common stock.
- Adjustments: The exercise price and number of shares are subject to adjustment for stock dividends, splits, combinations, or reclassifications, but will not be adjusted below the par value of the common stock.
- Fundamental Transactions: In the event of fundamental transactions, holders have the right to receive the same consideration as if they held the underlying shares immediately prior to the transaction.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the proceeds of the offering and the satisfaction of closing conditions. Management expects the closing to occur on or about February 13, 2026, subject to customary conditions. The Company disclaims any obligation to update these statements.
Risks include market conditions, the satisfaction of closing conditions, and general economic, industry, or political conditions. Detailed risk factors are referenced in the Company's most recent Form 10-Q and the final prospectus supplement filed on February 12, 2026.
Investor Verification Checklist
- Verify the final closing of the offering and the actual net proceeds received.
- Review the final prospectus supplement (filed February 12, 2026) for updated risk factors and use of proceeds.
- Monitor the Company's cash position and burn rate to assess the runway provided by the $37.1 million in estimated proceeds.
- Check for any subsequent filings regarding the exercise of pre-funded warrants and the resulting dilution to existing shareholders.